US2018344679A1PendingUtilityA1

Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations

69
Assignee: NOVARTIS AGPriority: Nov 9, 2005Filed: Jun 12, 2018Published: Dec 6, 2018
Est. expiryNov 9, 2025(expired)· nominal 20-yr term from priority
Inventors:Lili FengSven Erik GodtfredsenPaul Allen SuttonMahavir PrashadMichael John GirgisBin HuYugang LiuThomas J. BlacklockPiotr H. Karpinski
A61P 3/10A61P 5/24A61P 3/06A61P 7/12A61P 9/08A61P 9/12A61P 9/06A61P 5/42A61P 9/10A61P 9/00A61P 43/00A61P 9/14A61P 9/04A61P 27/06A61P 3/00A61P 25/28A61P 25/06A61P 3/04A61P 27/02A61P 25/00A61P 13/12A61P 17/00A61P 13/02A61P 11/00A61K 45/06A61K 31/216C07D 257/04A61K 31/4422A61K 31/5415A61K 31/41A61K 2300/00C07C 233/47C07D 207/50
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A dual-acting compound comprising:
 (a) an angiotensin receptor antagonist;   (b) a neutral endopeptidase inhibitor (NEPi); and optionally   (c) a pharmaceutically acceptable cation.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.